SCHEMBL5616139

SCHEMBL5616139

Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(C(=O)NCc4ccncc4)cc3)ncn2)ccc1F

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 8/20 0.78
▸ MMP10 P09238 1/20 0.68
▸ MMP9 P14780 1/20 0.68
▸ MMP8 P22894 1/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ GAA P10253 1/20 0.51
▸ LMNA P02545 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ CYP3A4 P08684 3/20 0.49
▸ MAPK14 Q16539 3/20 0.49
▸ MMP2 P08253 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5615854 0.96 MMP13 (0.86) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL14602302 0.89 MMP13 (0.75) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL5616136 0.89 MMP13 (0.78) MMP13MMP10MMP9MMP8LMNA
SCHEMBL5615881 0.89 MMP13 (0.82) MMP13MMP10MMP9MMP8
SCHEMBL8358823 0.89 MMP13 (1.00) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL29838134 0.89 MMP13 (1.00) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL5615610 0.88 MMP13 (0.77) MMP13MMP10MMP9MMP8ALDH1A1
SCHEMBL15647278 0.88 MMP13 (0.86) MMP13MMP10MMP9MMP8
SCHEMBL4717299 0.86 MMP13 (0.73) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL8357428 0.86 MMP13 (0.90) MMP13MMP10MMP9MMP8L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166609-B2 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-01-23 — — US claimed
US-20040167120-A1 Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 — — US claimed
US-7166609-B2 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-01-23 — — US disclosed
US-7166609-B2 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-01-23 — — US disclosed
US-7166609-B2 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-01-23 — — US disclosed
US-20040167120-A1 Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167120-A1 Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases MMP13, DPYD, MMP1 MMP13 1/4885MMP10 15/4885MMP9 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback